Oramed Pharmaceuticals Inc.: Oramed Completes Patient Enroll

Oramed Pharmaceuticals Inc.: Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

ORMD-0801 positioned to potentially be the first FDA approved oral insulin for the treatment of diabetes Completed enrollment of 710 patients for the Phase 3 ORA-D-013-1 study Top

Related Keywords

United States , Israel , Nadav Kidron , Eric Goldstein , Zach Herschfus , Exchange Commission , Prnewswire Oramed Pharmaceuticals Inc , Drug Administration , Oramed Pharmaceuticals , Oramed Pharmaceuticals Nasdaq , Nasdaq , Protein Oral Delivery , Oramed , Pharmaceuticals , Ompletes , Patient , Enrollment , Pivotal , Hase , Mural , Insulin , Study ,